Clinical Trials Logo

Immune System Diseases clinical trials

View clinical trials related to Immune System Diseases.

Filter by:

NCT ID: NCT04386395 Completed - SARS-CoV-2 Clinical Trials

Immune Changes in Severe COVID-19 Pulmonary Infections

COVIDIMM
Start date: March 30, 2020
Phase:
Study type: Observational

SARS-CoV-2 outbreak causes a spectrum of clinical patterns that varies from asymptomatic infection to mildly symptomatic manifestations and more-severe forms that need intensive care. Until now, the immune response to SARS-CoV-2 virus infection has been poorly reported to help decision for immune modulation therapies. As a consequence, trials have been designed to test both anti-inflammatory molecules as steroids or anti-bodies against IL-6, and others proposing to "boost" immunity with interferon beta based on similar inclusion criteria. The immune response to infective agents including viruses may have a complex time evolution with early and late phases corresponding to different patterns, oscillating between pro-inflammation and immune-depression. The potential window to improve outcome in COVID-19 by therapeutic intervention aimed at a fine tuning between immune toxicity and immunodepression requires a longitudinal assessment during the course of illness, especially for the patients who develop acute respiratory failure. Immune monitoring of both innate and adaptive immunity would then be essential to appropriately design clinical trials. The whole blood cells evaluation was recorded according to the time intervals between the onset of symptoms and the sampling after ICU admission. Patients' care was standardized, especially with regard to ventilation, sedation, and antimicrobial treatment. In this study the investigators prospectively perform a longitudinal study of both innate and adaptive immunity on patients admitted to ICU for an COVID-19 related acute respiratory failure. The data will be analyzed in reference to the onset of initial symptoms and also to the admission in ICU. The primary end point is the evolution of the characterization of monocytes and their subsets in term of number and expression of HLA-DR. A similar approach is used for lymphocytes and their subtypes with in addition, an ex vivo testing of their capabilities to be stimulated by SARS-CoV-2 viral proteins in term of TNFalpha, INFgamma, and IL1beta production. The secondary end-point was to test the association with outcomes and other non-specific markers of inflammation as CRP (C reactive protein), PCT (procalcitonin), DDimers and ferritin.

NCT ID: NCT04103099 Completed - Clinical trials for Immune System Diseases

Impact of HLNatural Immune Supplement on Colds

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

According to the Centers of Disease Control and Prevention (CDC) adults will have an average of 2-3 colds per year. Most colds will last approximately 7-10 days. The symptoms of colds could include cough, sore throat, runny nose, body aches, fevers, headaches and fatigue. A cold can affect your activity such as going to work, interrupting your sleep and your day to day activities. The test product contains all natural ingredients which have been combined into a powder to be taken in water at the sign of a cold.

NCT ID: NCT04094259 Completed - Clinical trials for Auto-Immune Diseases

Alternative Care in Patients With Auto-Immune Diseases

Alter-MAI
Start date: September 9, 2019
Phase:
Study type: Observational

Patients followed in Internal Medicine bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with in the department of Internal Medicine A

NCT ID: NCT03997175 Completed - Clinical trials for Immune System Diseases

Effect of Modified Playground Environment on Health, Particularly Immune System

ImmunoG1
Start date: April 15, 2018
Phase: N/A
Study type: Interventional

Children were exposed to biodiverse material or non-diverse material in sand pits. The two arms were compared. Immune response and bacterial markers were followed.

NCT ID: NCT03994302 Completed - Adverse Drug Event Clinical Trials

Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)

APSTOX
Start date: June 1, 2019
Phase:
Study type: Observational [Patient Registry]

Several drugs and chemotherapies seem to have an impact on the immune system. This study investigates reports of immune toxicities such as antiphospholipid syndrome, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

NCT ID: NCT03930017 Completed - Influenza Clinical Trials

Pregnancy, Arsenic and Immune Response

PAIR
Start date: October 14, 2018
Phase:
Study type: Observational

As the global availability of vaccines increases, and reaches areas disproportionately affected by arsenic and malnutrition, resolving questions about potential environmental and biologic barriers to maternal immunization has become increasingly urgent. It is not known whether arsenic, a known developmental toxicant, can alter maternal immune responses to vaccination and whether exposure to arsenic during pregnancy can impair the transfer of maternal vaccine-induced antibody to the newborn. Moreover, factors known to affect arsenic metabolism and toxicity outcomes, particularly micronutrients critical in one-carbon metabolism, have not been evaluated in studies of arsenic immunotoxicity and vaccine-induced protection in mothers and their newborns. The objective in this study is to investigate whether maternal arsenic exposure and one-carbon metabolism micronutrient deficiencies alter maternal and newborn measures of vaccine-induced protection, respiratory morbidity, and systemic immune function following influenza vaccination during pregnancy.

NCT ID: NCT03922087 Completed - Obesity Clinical Trials

No-worry Baby Project

Start date: November 20, 2018
Phase:
Study type: Observational

The Huizhou mother-infant cohort was set up to investigate the effect of dietary factors and environmental exposures during pregnancy on health consequences of mothers and offsprings in Huizhou, China.

NCT ID: NCT03901664 Completed - Autoimmune Diseases Clinical Trials

Lymphocyte Sub-populations and Auto Immune Diseases

SPLIT
Start date: February 1, 2018
Phase:
Study type: Observational

To determine if artificial intelligence allow to detect lymphocyte subpopulations specific of diseases (such as primary Sjogren' syndrome and systemic lupus erythematosus) among patients with suspicion of autoimmune diseases.

NCT ID: NCT03815357 Completed - Clinical trials for Primary Immunodeficiency

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Start date: January 31, 2017
Phase:
Study type: Observational

This is a multicentre prospective audit to determine the incidence of immunodeficiency in children with IPD. Aims and/or research question of the project 1. To determine the incidence of primary immunodeficiency in children >2 years who present with IPD 2. To determine the types of immunodeficiency associated with IPD in children

NCT ID: NCT03780712 Completed - Malaria Clinical Trials

Immune Dysfunction in Newborn Sepsis

RECIPAL
Start date: April 17, 2016
Phase:
Study type: Observational

The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.